Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial

Vanita R Aroda; Guillermo González-Galvez; Randi Grøn; Natalie Halladin; Martin Haluzík; György Jermendy; Adri Kok; Petra Őrsy; Mohamed Sabbah; Giorgio Sesti; Robert Silver

doi:10.1016/s2213-8587(19)30184-6

Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(19)30184-6 ◽

2019 ◽

Vol 7 (8) ◽

pp. 596-605 ◽

Cited By ~ 15

Author(s):

Vanita R Aroda ◽

Guillermo González-Galvez ◽

Randi Grøn ◽

Natalie Halladin ◽

Martin Haluzík ◽

...

Keyword(s):

Type 2 Diabetes ◽

Randomised Controlled Trial ◽

Insulin Glargine ◽

Controlled Trial ◽

Insulin Degludec ◽

Open Label ◽

Open Label Phase ◽

Randomised Controlled

Download Full-text

Review for "Higher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: results of a multicentre, open‐label, randomised controlled trial (BEYOND VII)"

10.1111/dom.13967/v1/review6 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Randomised Controlled Trial ◽

Insulin Glargine ◽

Controlled Trial ◽

Chinese Patients ◽

Open Label ◽

Starting Dose ◽

Randomised Controlled

Download Full-text

Review for "Higher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: results of a multicentre, open‐label, randomised controlled trial (BEYOND VII)"

10.1111/dom.13967/v1/review4 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Randomised Controlled Trial ◽

Insulin Glargine ◽

Controlled Trial ◽

Chinese Patients ◽

Open Label ◽

Starting Dose ◽

Randomised Controlled

Download Full-text

Review for "Higher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: results of a multicentre, open‐label, randomised controlled trial (BEYOND VII)"

10.1111/dom.13967/v2/review2 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Randomised Controlled Trial ◽

Insulin Glargine ◽

Controlled Trial ◽

Chinese Patients ◽

Open Label ◽

Starting Dose ◽

Randomised Controlled

Download Full-text

Review for "Higher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: results of a multicentre, open‐label, randomised controlled trial (BEYOND VII)"

10.1111/dom.13967/v2/review1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Randomised Controlled Trial ◽

Insulin Glargine ◽

Controlled Trial ◽

Chinese Patients ◽

Open Label ◽

Starting Dose ◽

Randomised Controlled

Download Full-text

Review for "Higher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: results of a multicentre, open‐label, randomised controlled trial (BEYOND VII)"

10.1111/dom.13967/v1/review8 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Randomised Controlled Trial ◽

Insulin Glargine ◽

Controlled Trial ◽

Chinese Patients ◽

Open Label ◽

Starting Dose ◽

Randomised Controlled

Download Full-text

Decision letter for "Higher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: results of a multicentre, open‐label, randomised controlled trial (BEYOND VII)"

10.1111/dom.13967/v1/decision1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Randomised Controlled Trial ◽

Insulin Glargine ◽

Controlled Trial ◽

Chinese Patients ◽

Open Label ◽

Starting Dose ◽

Randomised Controlled

Download Full-text

Review for "Higher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: results of a multicentre, open‐label, randomised controlled trial (BEYOND VII)"

10.1111/dom.13967/v3/review1 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Randomised Controlled Trial ◽

Insulin Glargine ◽

Controlled Trial ◽

Chinese Patients ◽

Open Label ◽

Starting Dose ◽

Randomised Controlled

Download Full-text

Author response for "Higher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: results of a multicentre, open‐label, randomised controlled trial (BEYOND VII)"

10.1111/dom.13967/v2/response1 ◽

2019 ◽

Author(s):

Linong Ji ◽

Hailong Wan ◽

Binhong Wen ◽

Xueying Wang ◽

Junfen Wang ◽

...

Keyword(s):

Type 2 Diabetes ◽

Randomised Controlled Trial ◽

Insulin Glargine ◽

Controlled Trial ◽

Author Response ◽

Chinese Patients ◽

Open Label ◽

Starting Dose ◽

Randomised Controlled

Download Full-text

Review for "Higher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: results of a multicentre, open‐label, randomised controlled trial (BEYOND VII)"

10.1111/dom.13967/v1/review1 ◽

2019 ◽

Author(s):

Bingli Liu

Keyword(s):

Type 2 Diabetes ◽

Randomised Controlled Trial ◽

Insulin Glargine ◽

Controlled Trial ◽

Chinese Patients ◽

Open Label ◽

Starting Dose ◽

Randomised Controlled

Download Full-text

Author response for "Higher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: results of a multicentre, open‐label, randomised controlled trial (BEYOND VII)"

10.1111/dom.13967/v3/response1 ◽

2020 ◽

Author(s):

Linong Ji ◽

Hailong Wan ◽

Binhong Wen ◽

Xueying Wang ◽

Junfen Wang ◽

...

Keyword(s):

Type 2 Diabetes ◽

Randomised Controlled Trial ◽

Insulin Glargine ◽

Controlled Trial ◽

Author Response ◽

Chinese Patients ◽

Open Label ◽

Starting Dose ◽

Randomised Controlled

Download Full-text